A Study of LY3002813 in Participants With Alzheimer's Disease

Inclusion Criteria:

- Healthy Participants:

- Overtly healthy males, as determined by medical history and physical examination,
willing to use a reliable method of birth control and will not donate sperm
during the study

- Between 18 to 40 years old.

- Body Mass Index (BMI) of between 18.0 and 30.0 kilogram per meter square
(kg/m^2), inclusive

- Participants with Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or AD:

- Present with mild cognitive impairment (MCI) due to AD or mild-to-moderate AD

- Men or nonfertile women, at least 50 years of age. Nonfertile is defined as
hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year

- Have a caregiver/study informant who provides a separate written informed consent
to participate

- Have adequate vision and hearing for neuropsychological testing in the opinion of
the investigator

- Positive florbetapir scan

Exclusion Criteria:

-Healthy Participants: Have a history or presence of cardiovascular, respiratory, hepatic,
renal, gastrointestinal, endocrine, hematological, immunological, or neurological disorders
capable of significantly altering the absorption,metabolism, or elimination of drugs; of
constituting a risk when taking the study medication; or of interfering with the
interpretation of data

- Participants with Mild Cognitive Impairment Due to AD or AD:

- Do not have a reliable caregiver/study informant who is in frequent contact with
the participant, who will accompany the participant to the office and/or be
available by telephone at designated times, and will monitor administration of
prescribed medications

- Are being monitored for radiation due to occupational exposure to ionized
radiation, or exposure to ionizing radiation within last 12 months from an
investigational study

- History within the past 5 years of a primary or recurrent malignant disease with
the exception of resected cutaneous squamous cell carcinoma in situ, basal cell
carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal
prostate-specific antigen post resection

- All Participants:

- History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous
malformation, or carotid artery occlusion, or stroke or epilepsy

- Have any contraindications for magnetic resonance imaging (MRI) studies,
including claustrophobia, the presence of contraindicated metal (ferromagnetic)
implants, cardiac pacemaker

- Have allergies to humanized monoclonal antibodies, including proteins and
diphenhydramine, epinephrine, and methylprednisolone

- Have gamma globulin therapy within the last year

- Previously dosed in any other study investigating active immunization against
amyloid beta (Aβ)

- Previously dosed in any other study investigating passive immunization against Aβ
within the last 6 months